Overview of planned and ongoing clinical studies of vaccines for COVID-19

Table of contents

RNA vaccines

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
mRNA-1273, Moderna Sponsor: National institute of Allergy and Infectious diseases; Moderna Therapeutics; Lonza	NCT04283461	United States, Washington	Phase 1 open label dose ranging study of the safety and immunogenicity of 2019 nCoV vaccine (mRNA1273) in healthy adults N=155, several doses are being tested: 10 mcg, 25 mcg, 50 mcg, 100 mcg, 250 mcg	Relevant safety outcomes; 12 months follow-up	Recruiting Estimated primary completion: November 2021	High
mRNA-1273 Sponsor: ModernaTX, Inc. NIAID Lonza	NCT04405076 Early news. https://time.com/5835785/moderna-coronavirus-vaccine-phase-2/ https://investors.modernatx.com/news-releases/news-release-details/moderna-receives-fda-fast-track-designation-mrna-vaccine-mrna https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine	United states (multiple sites)	Phase 2a, randomized, observer-blind, placebo controlled, dose-confirmation study to assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 SARS-COV-2 vaccine in adults 18 years of age or older. N=600 randomized to 50 mcg mRNA-1273 or 100 mcg mRNA-1273. Each participant will receive two shots The randomisation is stratified by age. 300 individuals 18-54 years and 300 individuals 55+ years	1. Solicited local and systemic adverse reactions [Time Frame: 7 days post-vacc] 2. Unsolicited adverse events [Time Frame: 28 days post-vacc] 3. Medically-attended adverse events [Time Frame: Month 0 through Month 13] 4. Serious adverse events [Time Frame: Month 0 through Month 13] 5. Change in the measure of clinical safety laboratory values in Cohort 2 from baseline [Time Frame: Through 1 month after last vacc] 6. Number and percentage of participants with abnormalities in blood pressure, temp, HR or respiratory rate [Time Frame: Through 1 year after last vacc] 7. Number and percentage of participants with abnormalities in physical examinations [Time Frame: Through 1 year after last vaccination] 8. Evaluate immunogenicity of mRNA-1273 by titer of SARS-CoV-2-specific binding antibody (bAb) measured by enzyme-linked immunosorbent assay (ELISA) [Time Frame: Through 1 year after the final dose]	Active, not recruiting Estimated Primary Completion Date: March 2021	High

mRNA-1273 Sponsor: Moderna Collaborators: Biomedical Advanced Research and Development Authority National Institute of Allergy and Infectious Diseases (NIAID)	NCT04470427 Early news https://investors.modernatx.com/news-releases/news-release-details/moderna-advances-late-stage-development-its-vaccine-mrna-1273/	Multicenter study in US	A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older N=30,000 Participants will receive 1 intramuscular (IM) injection of 100 microgram (ug) mRNA-1273 or placebo on Day 1 and on Day 29.	Number of Participants with a First Occurrence of COVID-19 Starting 14 Days after Second Dose of mRNA-1273 [Time Frame: Day 29 (second dose) up to Day 759 (2 years after second dose)] Number of Participants with Adverse Events (AEs) or Medically Attended AEs (MAAEs) Leading to Withdrawal [Time Frame: Up to Day 759 (2 years after second dose)] Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [Time Frame: Up to Day 8 (7 days after first dose) and up to Day 36 (7 days after second dose)] Number of Participants with Unsolicited AEs [Time Frame: Up to Day 57 (28 days after each dose)]	Including patients from July 27, 2020 onwards Estimated Primary Completion Date: October 27, 2022	High

Vaccine, Sponsor	**Study identifier/link to website**	**Location**	**Study design**	**Primary outcome**	**Status of trial**	**Importance**
BNT162, BioNTech BioNTech mRNA vaccine BNT162a1 BNT162b1 BNT162b2 BNT162c2 Pharmaceuticals GmbH + Pfizer Inc.	EudraCT Number: 2020-001038-36 NCT04380701 U1111-1249-4220 BNT162-01 https://investors.biontech.de/news-releases/news-release-details/biontech-and-pfizer-announce-regulatory-approval-german	Germany	Phase I/II, multi-site, non-randomized, open-label trial investigating the safety and immunogenicity of four prophylactic SARS-CoV-2 RNA vaccines against COVID-2019 using different dosing regimens in healthy adults. N=200 The trial has two parts. Part A: a dose-finding part with four dose cohorts for each vaccine and one pre-defined and one optional dose level for a de-escalation approach. - BNT162a1 (i.m., escalating dose levels)	1. Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 days after each immunization. 2. Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 days after each immunization. 3. The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): [Time Frame: 21	Ongoing; Estimated Primary Completion Date: August 2020	High

			- BNT162b1 (i.m., escalating dose levels) - BNT162b2 (i.m., escalating dose levels) - BNT162c2 (i.m., single dose) Part B: dedicated to recruit expansion cohorts with dose levels which are selected from data generated in Part A.	days following dose administration] 4. The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): [Time Frame: 28 days following dose administration]		
BNT162 BioNTech mRNA vaccine BNT162a1 BNT162b1 BNT162b2 BNT162c2 Sponsor: Biontech SE	NCT04368728 Same vaccine as 2020-001038-36	Multicenter, Germany, United States	Phase 1/2, observer-blinded, placebo-controlled, randomized dose-finding trial to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of Covid-19 RNA Vaccine Candidates Against COVID-19 in Healthy Adults N = 7600 healthy adults in age groups: 18-55, 65-85 and 18-85. Randomized to receive single dose of low-, medium- or high-dose or two doses of low-, medium- or high-dose of BNT162a1, BNT162b1, BNT162b2, BNT162c2 or placebo injection (21 arms)	Percentage of participants reporting: - Local reactions - Systemic events - (Serious) Adverse events Percentage of sentinel cohort participants with grading shifts and abnormal hematology and laboratory values	Recruiting Estimated primary Completion Date: June 28, 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
RNA vaccine, Imperial College London LNP-nCoVsaRNA	https://www.imperial.ac.uk/covid-19-vaccine-trial/ ISRCTN17072692	UK	In total, Phase I will enrol approximately 120 adult volunteers across the UK.		Planned to start mid June and last for 2 months Interim results available end of August	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
CVnCoV, CureVac Sponsor: Curevac, CEPI	NCT04449276	Germany	A Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults	Safety	Recruiting; Estimated primary completion: August 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
People's Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.	ChiCTR2000034112	Zhejiang and Guangxi Zhuang Autonomous Region, China	A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18-59 years and 60 years and above N=168	IgG antibody, Neutralizing antibody, cellular immunity	From 2020-06-25 To 2021-12-31	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
LUNAR-COV19, Arcturus Therapeutics and Duke-NUS	NCT04480957	Singapore	A Phase 1/2 Randomised, Double Blinded, Placebo Controlled, Ascending Dose Study to Assess the Safety, Tolerability, and Immunogenicity of ARCT-021 in Healthy Adult Subjects N=85 randomised to 3 different doses and 2 different dosing regimen	Incidence, severity and dose-relationship of AEs [Time Frame: 56 days]	Estimated primary completion: July 2020	High

DNA vaccines

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
INO-4800, Inovio Device: CELLECTRA® 2000 Sponsor: Inovio Pharmaceuticals	NCT04336410	United States, Kentucky, Missouri and Pennsylvania	Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800 for a Novel Coronavirus (COVID-19) in Healthy Volunteers N=40 Two different doses will be tested	Safety and efficacy Time frame week: 52	Recruiting; Estimated Primary Completion: July 2021	High
INO-4800 Sponsor: International Vaccine Institute	NCT04447781	Not stated yet	A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800 N=160 participants	Safety and efficacy Time frame week: 52	Not yet recruiting; Estimated primary completion: February 22, 2022	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
GX-19, Genexine Sponsor: Genexine, Inc.	NCT04445389	Korea	A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19 N=190	Incidence of solicited adverse events [Time Frame: Through 1 year post vaccination] Incidence of unsolicited adverse events [Time Frame: Through 1 year post vaccination] Incidence of serious adverse events [Time Frame: Through 1 year post vaccination]	Recruiting; Estimated Primary Completion: May 17, 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
DNA plasmid vaccine, Cadila Healthcare Limited	CTRI/2020/07/026352	India	A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate N=1048	Phase I: To evaluate the safety of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. (day 0 and day 84) Phase II: To evaluate the immunogenicity of Novel Corona Virus-2019-nCov Vaccine Candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects compared to placebo. (day 0 and day 224)	Recruiting; Estimated Primary Completion: May 17, 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
AG0301-COVID19, Osaka University/AnGes/Takara Bio	JapicCTI-205328 https://www.clinicaltrials.jp/cti-user/trial/ShowDirect.jsp?clinicalTrialId=30761 NCT04463472	Osaka City University Hospital, Japan	Phase 1 A Non-randomized, Open-label, Non-controlled Phase I/II Study to Assess Safety and Immunogenicity of Two Doses of Intramuscular AG0301-COVID19 (1mg/2mg) in Healthy Adults N=30	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [Time Frame: Week 1 through Week 9] Immunogenicity [Time Frame: Weeks 3, 5, 7, 9]	Recruiting Estimated primary completion date: September 26, 2020 Duration: 25.6.2020-31.7.2021	High

Non-replicating viral vector

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Ad5-nCoV, CanSino Recombinant Novel Coronavirus Vaccine, Adenovirus Type 5 Vector Sponsor: CanSino Biologics Inc.	ChiCTR2000030906 NCT04313127	Hubei, China	A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus (2019-COV) vaccine (adenoviral vector) N=108 Healthy adults treated with 3 different doses	Adverse reactions 7 days post injection	Active, not recruiting Estimated primary completion: Dec 30 2020	High
Ad5-nCoV Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China CanSino Biologics Inc.	NCT04341389 ChiCTR2000031781	China, Hubei	A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years N=500 healthy individuals randomised to 1×10^11vp of Ad5-nCoV 5×10^10vp of Ad5-nCoV Placebo	Occurrence of adverse reactions [Time Frame: 0-14 days post vaccination] Anti SARS-CoV-2 S antibody response(ELISA) [Time Frame: 28 days post vaccination] Neutralizing antibody response to SARS-CoV-2 [Time Frame: 28 days post vaccination]	Active, not recruiting; Estimated Primary Completion: January 31, 2021	High
Ad5-nCoV Sponsor and collaborators: CanSino Biologics Inc. Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China Canadian Center for Vaccinology	NCT04398147 Early news https://thesamikhsya.com/exclusive/canada-approves-first-clinical-trial-for-potential-covid-19-vaccine	Canada	Phase I /II adaptive clinical trial to evaluate the safety, tolerability and the Immunogenicity of Ad5-nCoV in healthy adults from 18 to <55 and 65 to <85 years of age with the randomized, observer-blind, dose-escalation design. N=96 will be included in the dose-escalating study (phase I) 5E10vp and 10E10vp, Of each of the 2 doses, single dose and 2 doses will be tested. N=600 will be included in the phase 2 trial	Solicited AE in all groups [Time Frame: 0-6 days after each vaccination] Unsolicited AE in all groups [Time Frame: 0-28 days after each vaccination] Serious adverse events (SAE) in all groups [Time Frame: 6 months after the final vaccination]	Not yet recruiting; Estimated Primary Completion: March 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
AZD1222, ChAdOx1 nCoV-19, Oxford and Astra-Zeneca (COV001) Based on adenovirus vaccine vector with SARS-CoV-2 spike protein. ChAdOx1 nCoV-19 is an adenoviral vector-based vaccine that consists of genetic material from SARS-CoV-2 inserted into a weakened common cold virus. The idea is that after a person has been vaccinated, the spike protein on the surface of the Covid-19 virus is produced, thereby preparing the immune system to attack it. University of Oxford Astra-Zeneca	NCT04324606 2020-001072-15 http://www.ox.ac.uk/news/2020-03-27-oxford-covid-19-vaccine-programme-opens-clinical-trial-recruitment	UK	A Phase I/II Study Single-blinded, randomised, placebo controlled, multi-centre study N: 510 Healthy volunteers aged 18-55 Number of study participants has been increased to 1112.	Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19 Occurrence of serious adverse events (SAEs) throughout the study duration	Active, not recruiting Estimated primary Completion: May 2021	High
AZD1222, ChAdOx1 nCoV-19	NCT04400838 2020-001228-32 Early news: http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iiiii-human-trials	UK	Phase II/III study to determine the efficacy, safety and immunogenicity of the ChAdOx1 nCoV-19 in healthy UK volunteers. A randomised, single blinded trial. 10,260 adults and children Phase 2 study: from 5 years of age Phase III study: from 18 years Comparator: Menveo or Nimenrix (meningococcal vaccines)	Assess the efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19 in adults aged 18 years and older. [Time Frame: 6 months]: Number of virologically confirmed (PCR positive) symptomatic cases of COVID-19 Assess the safety of the candidate vaccine ChAdOx1 nCoV-19 in adults and children [Time Frame: 6 months]: Occurrence of serious adverse events (SAEs) throughout the study duration.	Not yet recruiting; Estimated primary completion: August 2021	High

AZD1222, ChAdOx1 nCoV-19	NCT04444674 PACTR202006922165132	Multicentre study in South Africa	An Adaptive Phase I/II Randomized Placebo-controlled double-blinded Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV N=2000	Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-negative adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety) [Time Frame: Up to 12 months post enrollment] Determine if there is a reduction of severe and non-severe COVID-19 disease in HIV-negative adults who receive candidate vaccine ChAdOx1 nCoV-19 compared to placebo recipients (efficacy) [Time Frame: Up to 12 months post enrollment] Assess the incidence of adverse events (intervention-related and intervention-unrelated) in HIV-positive adults aged 18-65 year receiving candidate ChAdOx1 nCoV-19 vaccine or placebo (safety) [Time Frame: Up to 12 months post enrollment] Assess cellular Immunogenicity of ChAdOx1 nCoV-19 in people living with HIV (immunogenicity) [Time Frame: Up to 12 months post enrollment] Assess humoral immunogenicity of ChAdOx1 nCoV-19 in people living with HIV [Time Frame: Up to 12 months post enrollment]	Not yet recruiting; Estimated Primary Completion: October 2020	High
ChAdOx1 nCoV-19 vaccine vs MenACWY vaccine	ISRCTN89951424	Brazil	A phase III randomized controlled trial to determine safety, efficacy, and immunogenicity of the non-replicating ChAdOx1 nCoV-19 vaccine Single-blind	Virologically confirmed (PCR positive) symptomatic cases of COVID-19 over the course of 12 months.	Ongoing Study duration May 2020 to July 2021	High

			Participants will be randomised (1:1 using block randomisation) to receive either ChAdOx1 nCoV-19 or MenACWY (licensed control vaccine). Participants will also be advised to take paracetamol for 24 hours after vaccination if there are no contraindications to doing so. N=2000	All participants will be invited to follow-up visits at day 28, 90, 182 and 364 and participants will be asked to contact the study team if they develop symptoms suggestive of COVID-19 at any point during the trial. Symptomatic participants will be asked to present for a visit to test for SARS-CoV-2 PCR.		

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Gam-COVID-Vac Lyo, Gamaleya Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Adenovector virus	NCT04437875	Moscow, Russian Federation	An open, prospective, two-stage, non-randomized, first-phase study involving healthy volunteers N=38 3 arms: rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene. Prime-boost: Day 1 rAd26 Component Day 21 rAd5 Component	The changing of antibody levels against the SARS-CoV-2 glycoprotein S at 42 days [Time Frame: at days 0, 14, 21, 28, 42] Number of Participants With Adverse Events [Time Frame: through the whole study, an average of 180 days]	Active, not recruiting Estimated primary Completion: August 5, 2020	High
Gam-COVID-Vac Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Adenovector virus	NCT04436471	Moscow, Russian Federation	An open, prospective, two-stage, non-randomized, first-phase study involving healthy volunteers N=38 3 arms: rAd26 Component, 1 vaccination Component 1 consists of a recombinant adenovirus vector based on the human adenovirus type rAd5 Component, 1 vaccination Component 2 consists of a vector based on the human adenovirus type 5, containing the SARS-CoV-2 S protein gene. Prime-boost: Day 1 rAd26 Component Day 21 rAd5 Component	Changing ofantibody levels against the SARS-CoV-2 glycoprotein S in 42 days [Time Frame: at days 0,14, 21, 28, 42] Number of Participants With Adverse Events [Time Frame: through the whole study, an average of 180 days]	Recruiting Estimated primary Completion: August 5, 2020	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Ad26.COV2-S, JnJ Sponsor: Johnson & Johnson	https://www.janssen.com/johnson-johnson-announces-acceleration-its-covid-19-vaccine-candidate-phase-12a-clinical-trial-begin	US and Belgium	The randomized, double-blind, placebo-controlled Phase 1/2a study will evaluate the safety, reactogenicity (response to vaccination), and immunogenicity (immune response) of the investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant in 1045 healthy adults aged 18 to 55 years, as well as adults aged 65 years and older. The study will take place in the U.S. and Belgium.		Is expected to commence in second last half of July 2020	High

Inactivated virus

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Wuhan Institute of Biological Products, Sinopharm Inactivated vaccine (Vero cells) Henan Provincial Center for Disease Control and Prevention Funding: Ministry of Science and Technology, China	ChiCTR2000031809	China, He'nan , Jiaozuo	Randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) Healthy volunteers, from 6 years of age Multiple doses	Incidence of adverse reactions/events	From 2020-04-11 To 2021-11-10	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Beijing Institute of Biological Products, Sinopharm Inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) Sponsor: Henan Provincial Center for Disease Control and Prevention Funding: Ministry of Science and Technology, China and Sinopharm	ChiCTR2000032459	China, He'nan, Shangqiu	A phase 1/2 randomized, double-blind, placebo parallel-controlled clinical trial to evaluate the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) N = 2128??? Healthy volunteers from 3 years of age Multiple doses	Incidence of adverse reactions/events	From 2020-04-28 To 2021-11-28	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Primary sponsor: China National Biotec Group Co.Ltd Secondary sponsors: Beijing Institute of Biological Products Co., LTD., Wuhan Institute of Biological Products co., LTD. Shaikh Khalifa Medical City Dialysis Center	ChiCTR2000034780	Abu Dhabi, UAE	Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and above 15000 subjects randomized 1:1:1 to two different treatment groups or placeno	Protective efficacy against COVID 19 measured 14 after full course of vaccination	Recruiting; Duration: 2020-07-16 To 2021-07-15	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Chinese Academy of Medical Sciences Inactivated SARS-CoV-2 vaccine; Sponsors and Collaborators: Chinese Academy of Medical Sciences, West China Second University Hospital, Yunnan Center for Disease Control and Prevention	ChiCTR2000032459 NCT04412538	China, Sichuan	Randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial N =942 healthy volunteers from 18-59 years of age: N=192 in the phase I trial, and N=750 in the phase II trial. Multiple doses, 2 different schedules	Incidence of adverse reactions/events Serum conversion rate of neutralizing antibodies and IgG antibodies in the phase II trial at day 14 and 28	Recruiting; Estimated primary completion date: September 2020	High
Chinese Academy of Medical Sciences Sponsors and Collaborators Chinese Academy of Medical Sciences West China Second University Hospital Yunnan Center for Disease Control and Prevention	NCT04470609	China, Sichuan	A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged ⩾60 Years N=471 ranodmised to 1 of 3 doses or placebo. 1 dose at day 0 and 1 dose at day 28	Adverse reactions/events rate [Time Frame: 7 days after vaccination] Adverse reactions/events rate [Time Frame: 28 days after vaccination] Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIb [Time Frame: 28 days after vaccination] Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIb [Time Frame: 28 days after vaccination]	Enrolling by invitation Estimated Primary Completion Date: November 2020	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Coronavac, Sinovac Formalin-inactivated and alum-adjuvanted Sinovac Research & Development Co., Ltd	NCT04352608	China, Jiangsu	Randomized, double-blinded, and placebo controlled phase I/II clinical trial of the SARS-CoV-2 inactivated vaccine. Healthy adults aged 18-59 Years. N (estimated) = 744	1.Safety indexes of adverse reactions [Time Frame: up to 28 days after the whole schedule vaccination] 2.Neutralizing-antibody seroconversion rates for the emergency vaccination schedule (0 and 14) [Time Frame: The 14th day after two doses of vaccination] 3.Neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28) [Time Frame: The 28th day after two doses of vaccination]	Recruiting; Estimated Primary Completion Date: August 13, 2020	High
Coronavac Inactivated SARS-CoV-2 vaccine (Vero Cell) Sponsor: Sinovac Research and Development Co., Ltd.	NCT04383574	China, Hebei	Phase 1/2, double-blinded, placebo-controlled, randomized trial on Inactivated Vaccine for Prevention of Covid-19 infection N = 422 (72 in phase 1 and 350 in phase 2), age ≥ 60, healthy, randomized to two doses of low, medium or high dosage or placebo	Safety index-incidence of adverse reactions [Time Frame: Day 0-28 after each dose vaccination]	Not yet recruiting Estimated Primary Completion Date: July 20, 2020	High
Coronavac Sponsor: Sinovac Research and Development Co., Ltd. Collaborator. Butantan Institute	NCT04456595	Brazil	Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac N= 8870	Incidence of COVID-19 cases after two-doses immunization schedule [Time Frame: Two weeks after second dose up to one year after first dose] Number of virologically-confirmed symptomatic COVID-19 two weeks after second dose of vaccine Frequency of adverse events up to seven days after immunization [Time Frame: Seven days after each immunization] Frequency of adverse reaction in the seven days following each immunization per age group	Not yet recruiting; Estimated primary completion date: September 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
BBV152, Bharat Biotech Whole-Virion Inactivated SARS-CoV-2 Vaccine	CTRI/2020/07/026300 NCT04471519	India	Phase 1, followed by Phase 2 Randomized, Double-blind, Multicenter Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) in Healthy Volunteers. Whole-Virion Inactivated SARS-CoV-2 vaccine (BBV152) with three formulations, BBV152A, BBV152B and BBV152C. Dose: 0.5ml, Route of administration: Intramuscular injection, Frequency: Two doses at Day 0 and Day 14 N=1125	Phase 1: 1. The occurrence of immediate adverse events within two hours of vaccination 2. The occurrence of adverse events within 7 days of vaccination.3. The occurrence of any adverse events throughout the study duration 4. The occurrence of serious adverse events (SAEs) Phase 2: Primary 1. To evaluate the immunogenicity in terms of GMT and four-fold seroconversion rate amongst the two selected BBV152 vaccine formulations	Recruiting; Estimated Primary Completion Date: July 2021	High

Protein subunit

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
NVX-CoV2373, Novavax SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) Sponsor: Novavax CEPI funding	NCT04368988 https://ir.novavax.com/news-releases/news-release-details/novavax-identifies-coronavirus-vaccine-candidate-accelerates	Australia (multiple sites)	A 2-Part, phase 1/2, randomized, observer-blinded study to evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with or without MATRIX-M™ Adjuvant in healthy subjects. N=131 healthy subjects ≥ 18 to 59 age randomized to placebo or SARS-CoV-2 rS - 25 µg without Matrix-M or SARS-CoV-2 rS - 5 µg with 50 µg Matrix-M or SARS-CoV-2 rS - 25 µg with 50 µg Matrix-M or SARS-CoV-2 rS - 25 µg with 50 µg Matrix-M followed by Placebo. In Part 1, at least 1 and up to two SARS-CoV-2 rS constructs will be evaluated in up to 2 cohorts, which may be enrolled in parallel. An interim analysis of Part 1 safety and immunogenicity data will be performed prior to an optional expansion to Part 2.	1. Subjects with solicited AEs - Phase 1 [Time Frame: 28 2. Safety Laboratory Values (serum chemistry, hematology) - Phase 1 [Time Frame: 28 days] 3. Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) - Phase 1 [Time Frame: 35 days]	Recruiting Expected to start mid-May 2020 Estimated Primary Completion Date: December 31, 2020 Sharing of results in July 2020	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Native like Trimeric subunit Spike Protein vaccine, Clover/GSK/Dynavax SCB-2019 with and without adjuvant (AS03 or CpG 1018 plus Alum adjuvant) Sponsor: Clover Biopharmaceuticals Inc./GSK/Dynavax	NCT04405908	Australia	This is a randomized, double blind, placebo controlled, first-in-human study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects. Each study vaccine dose level will be evaluated with and without adjuvant. N=150 healthy volunteers stratified by age, randomised to 1 of 3 doses (3, 9 or 30 microgram with or without adjuvant)	Incidence of solicited adverse events (AEs) after vaccination [Time Frame: 7 days after the first or second vaccination.] Incidence of unsolicited AEs after vaccination [Time Frame: Day 1 to Day 50] Immunogenicity(Anti-SCB-2019 Antibody Titers) [Time Frame: Day 1 to Day 184] Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).	Recruiting; Estimated primary completion: October 20, 2020	High

				Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs) [Time Frame: Day 1 to Day 184]		

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Adjuvanted recombinant protein (RBDDimer), Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Collaborators: The Second Affiliated Hospital of Chongqing Medical University Beijing Chao Yang Hospital	NCT04445194	China, Chongqing	A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age. N=50	The number of adverse events after intramuscular injection [Time Frame: Up to one year after the last vaccination]	Recruiting; Estimated primary completion: July 21, 2021	High
Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.	NCT04466085		A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years N=900 randomised to Low dose, high dose or placebo injected as 2 doses or 3 doses	Neutralizing antibody positive conversion rate [Time Frame: 30 days after inoculation]	Not yet recruiting; Estimated Primary Completion Date; September 15, 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
COVAX19, Recombinant spike protein with Advax™ adjuvant, Vaxine Pty Ltd/Medytox	NCT04453852	Australia, South Australia	A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects. N=40	Incidence of Adverse Events [Time Frame: 1 weeks post immunisation] COVID19 neutralizing antibody titers [Time Frame: 2 weeks post second immunisation] COVID19 T cell immunogenicity [Time Frame: 3 weeks post second immunisation]	Recruiting; Estimated primary completion: July 1, 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Molecular clamp stabilized Spike protein with MF59 adjuvant University of Queensland/CSL/Seqirus	ACTRN12620000674932p	Australia	A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study To Evaluate The Safety And Immunogenicity Of An Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine (COVID-19 vaccine) In Healthy Adults Aged 18 To 55 Years Old N=120	Safety and tolerability	Recruiting; Estimated primary completion: July 1, 2021	High

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
KBP-COVID-19, Kentucky Bioprocessing, Inc RBD-based vaccine	NCT04473690	Not stated yet	A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-COVID-19 Vaccine in Healthy Seronegative Adults Aged 18-49 and 50-70. Two doses will be tested. N=180	Solicited Administration site reactions [Time Frame: 7 days after vaccination] Occurrence of Adverse Events Solicited systemic events [Time Frame: 7 days after vaccination]	Not yet recruiting; Estimated primary completion: December 3, 2020	High

Virus Like Particles

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
Plant derived VLP, Medicago Inc./Université Laval	NCT04450004		A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age N=180	Safety measures + Neutralizing antibody [Time Frame: 21 days] Specific Th1 cell-mediated immunity (CMI) response [Time Frame: 21 days] Specific Th2 cell-mediated immunity (CMI) response [Time Frame: 21 days]	Recruiting; Estimated primary completion: September 12, 2020	High

Other vaccine studies, not yet recruiting

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
DNA vaccine: bacTRL-Spike Plasmids containing synthetic DNA encoding spike protein from SARS-CoV-2 Sponsor: Symvivo Corporation (A Vancouver-based biotech company) Sponsor: Symvivo Corporation	NCT04334980	Canada, British Columbia Canada, Nova Scotia	A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults N=84 3 different doses will be tested	Frequency of Adverse Events Each participant will remain in the trial for 12-13 month	Not yet recruiting; Estimated Primary Completion Date: August 31, 2021	High
Non-Replicating Viral Vector: Intranasal vaccine Single dose AdCOVID	Early news: Collaboration between University of Alabama at Birmingham and Altimune Inc. https://www.drugtargetreview.com/news/59182/biotech-and-academia-collaborate-on-intranasal-covid-19-vaccine-development/	USA	Phase I estimated to start Q3 2020	TBD	Not recruiting; Estimated study completion: Unknown	High
Dendritic Cell Vaccine Sponsor: Aivita Biomedical, Inc.	NCT04386252	Not stated	A phase 1/2, randomized, double-blinded trial of a vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF, to prevent COVID-19. Different doses N = 160 frontline healthcare providers and first responders.	Confirm safety [Time Frame: 6 months]	Not yet recruiting Estimated Primary Completion Date: October 2020	High
Drug: MicroRNA2911 Sponsor: Nanjing University	ChiCTR2000031432	China, Jiangsu	Phase 1, single center, randomized, open, dose-increasing, double-blind clinical study to evaluate the safety	Safety and tolerance	Not yet recruiting From 2020-04-01 To 2020-08-31	Medium

			and tolerance of microRNA2911 plasmid in healthy people. N = 15 healthy adults enrolled in 1-5 dose group to receive 3 times of intravenous infusion for 10 minutes of MicroRNA2911 once a day or every other day.			
V-SARS Sponsor: Immunitor LLC	NCT04380532	Canada	Phase I/II, single group assignment, open-label trial to evaluate the safety and immunogenicity in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. N=20 V-SARS administered po. once-per-day for 15 days	Effect on CBC as per CTCAE v4.0 [Time Frame: 15 Days] Effect on biochemistry parameters as per CTCAE v4.0 [Time Frame: 15 Days]	Recruiting Estimated Primary Completion Date: May 15, 2021	Medium

Other vaccines

Vaccine, Sponsor	Study identifier/link to website	Location	Study design	Primary outcome	Status of trial	Importance
BCG vaccine Licensed for tuberculosis	NCT04327206 Early news: The BRACE trial https://www.mcri.edu.au/BRACE https://www.clinicaltrialsarena.com/news/australia-bcg-vaccine-trial-covid-19/	Murdoch Children's Research Institute in Australia	Randomised, multi-center clinical trial to test the use of BCG vaccine against COVID-19 patients Will include 4.170 healthcare workers across AU, incl Melbourne Campus' Royal Children's Hospital	TBD BCG will be assessed for its ability to mitigate the prevalence and severity of COVID-19 symptoms.	Recruiting; Estimated primary completion: October 30, 2020	High
BCG vaccine University Medical Center, Netherlands	EudraCT: 2020-000919-69 NCT04328441 https://www.sciencemag.org/news/2020/	Netherlands	Randomised placebo controlled multi-center clinical trial to test the use of BCG vaccine as protection against COVID-19 Will include 1.000 healthcare workers across 8 Dutch hospitals	Study outcome: "unplanned absenteeism" as it will not be feasible to visit the sick professionals at home during the coronavirus pandemic	Ongoing; Estimated Primary Completion: October 25, 2020	High

	03/can-century-old-tb-vaccine-steel-immune-system-against-new-coronavirus		BCG often cause an injection site reaction which will unblind the person receiving BCG, but the researchers will remain blinded.	BCG will be assessed for its ability to mitigate the prevalence and severity of COVID-19 symptoms.		
BCG Vaccine VPM1002 Licensed for tuberculosis	Early news: http://www.mpiib-berlin.mpg.de/1990061/news_publication_14610776_transferred https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/serum-institute-to-test-if-tb-vaccine-vpm1002-is-effective-against-covid-19/articleshow/74800246.cms?from=mdr	Germany	Phase III, multi-centre clinical trial to test the use of BCG vaccine as protection against COVID-19 Likely to begin on 2.000 health-care workers in Germany and soon after in India as well.	Study outcome: BCG will be assessed on healthcare workers to see efficacy of the vaccine as a preventive against coronavirus, and on elderly patients to check efficacy in reducing clinical severity	Unknown	High
BCG vaccine BCG vaccine is the Copenhagen (Danish strain) Sponsor: Ain Shams University	NCT04350931	Egypt	Single blind, randomised, placebo controlled trial. N=900 healthcare workers will be randomly assigned to receive intradermal injection of either BCG vaccine or normal saline.	Incidence of confirmed COVID-19 [Time Frame: 9 months] Estimate the incidence of confirmed COVID-19 among the healthcare workers in isolation hospitals Effectiveness of BCG vaccine [Time Frame: 9 months] Evaluate the effectiveness of BCG vaccine in protecting the healthcare workers in isolation hospitals against the risk of COVID-19 infection by detecting any positive cases among vaccinated healthscare workers	Not yet recruiting; Estimated Primary Completion: October 1, 2020	High
BCG Vaccine Sponsor: Andrew Dinardo	NCT04348370	United States: Massachusetts and Texas	Phase 4, randomized, double-blinded N=700 health care workers randomized 1:1 to BCG vaccine or placebo.	Incidence (measured by confirmed positive test) of SARS-CoV2 infection following BCG vaccination compared to placebo [Time Frame: Measured daily for up to 6 months]	Not yet recruiting Estimated Primary Completion Date: May 2021	High

BCG vaccine Sponsor: Universidad de Antioquia	NCT04362124	Columbia (multicenter)	Phase 3, double-blind, randomized, clinical trial to evaluate the BCG vaccination in healthcare workers to reduce the severity of SARS-COV-2 infection. N=1000 covid-19 negative health care workers randomized 1:1 to BCG vaccine or placebo.	Primary outcome [Time Frame: From date of randomization to 360 day of the study]	Not yet recruiting Estimated Primary Completion Date: June 2021	High
BCG vaccine of patients already positive for SARS-CoV-2 (non-specific effects) Sponsor: University of Campinas, Brazil	NCT04369794 (BATTLE)	Brazil	Phase 4, prospective, randomized, double-blind, multicentre study to evaluate to the impact of previous (priming effect, from the titer of anti-BCG interferon-gamma) or current BCG exposure (boost with intradermal vaccine) on 1) clinical evolution of COVID-19; 2) elimination of SARS-CoV-2 at different times and disease phenotypes; and 3) seroconversion rate and titration (anti-SARS-CoV-2 IgA, IgM, and IgG). N=1000 randomized to BCG vaccine or placebo.	1. Clinical evolution of COVID-19 [Time Frame: 45 days of symptoms onset or diagnosis] 2. SARS-CoV-2 elimination [Time Frame: 7 days of symptoms onset or diagnosis] 3. Seroconversion rate and titration [Time Frame: 7 days of symptoms onset or diagnosis	Not yet recruiting Estimated Study Completion Date: May 2022	High
BCG vaccine Sponsor: Bandim Health Project Collaborator: University of Southern Denmark	NCT04373291 2020-001888-90 BCG-DENMARK-COVID	Denmark	Using BCG vaccine to enhance nonspecific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. Phase 3, multi-center, randomized, double-blinded placebo-controlled trial using BCG Vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. N=1500 hospital personal ≥18 years caring for covid-19 patients randomized 1:1 to BCG vaccine (0,1 mL dose of BCG-Denmark, AJ Vaccines) or placebo (0.1 ml dose sterile 0.9 % NaCl).	Number of days of unplanned absenteeism for any reason [Time Frame: 6 months]	Not yet recruiting Estimated Study Completion Date: January 2021	High
Bacille Calmette-Guérin (BCG) Sponsor: TASK Applied Science	NCT04379336	South Africa	A phase 3, randomized, double-blinded, placebo-controlled study to reduce morbidity and mortality in health care workers exposed to SARS-CoV-2 by enhancing non-specific	Incidence of HCWs hospitalized due to COVID-19 per arm [Time Frame: 52 weeks]	Recruiting Estimated Primary Completion Date: April 28, 2021	High

			immune responses through bacillus calmette-guérin vaccination N = 500 healthcare workers			
BCG vaccinaton Sponsor: Assistance Publique - Hôpitaux de Paris	NCT04384549	France	Phase 3, single-blinded, placebo-controlled, randomized trial on the Efficacy of Vaccination With Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 Via the Strengthening of Innate Immunity in Health Care Workers N = 1120 healthcare workers in direct contact with Covid-19 patients	Incidence of documented COVID-19 among health care workers exposed to SARS CoV2 and vaccinated with BCG compared to placebo. [Time Frame: during the study period of 6 months]	Not yet recruiting Estimated Primary Completion Date: February 11, 2021	High
VPM1002 (Mycobacterium bovis rBCGΔureC::hly, live 2-8 × 105 CFU)	NCT04439045		A Randomized, Double-blind, Placebo-controlled Phase 3 Study N03626		Not yet recruiting Estimated Primary Completion: April 1, 2021	High
Previous Bacille Calmette-Guérin (BCG) vaccination Sponor: Assiut University	NCT04347876	Egypt	Observational, Case-Control study evaluating whether previous BCG vaccination can alter the outcome of COVID-19 cases. Based on Tuberculin Test. N = 100 COVID-positive patients admitted to hospital and ICU with positive Tuberculin Test compared to COVID-positive patients with negative Tuberculin Test.	Pneumonia severity index [Time Frame: 2 weeks] Need for ICU admission [Time Frame: 2 weeks]	Recruiting Estimated Study Completion Date: June 30, 2020	Low
VPM1002 (a further development of the BCG-vaccine) Sponsor: Vakzine Projekt Management GmbH	NCT04387409 VPM1002-DE-3.06CoV	Germany	Phase 3, double-blind, randomized, placebo-controlled multicentre trial to assess the efficacy and safety of VPM1002 in reducing healthcare professionals' absenteeism in the SARS-CoV-2 pandemic by modulating the immune system. N=1200 health care professionals with high expected exposure to SARSCoV-2 infected patients randomized 1:1 to a single dose (0.1 ml) of either VPM1002 or placebo.	Number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection) [Time Frame: From day 0 to day 240]	Not yet recruiting Estimated Primary Completion Date: June 30, 2021	High
BCG vaccination	NCT04417335	Netherlandes	Single blinded, placebo-controlled adaptive multi-centre randomized controlled trial N=2014 randomised to BCG vaccination or placebo	SARS-CoV-2 related hospital admission [Time Frame: Maximum of 1 year]	Active, not recruiting; Estimated primary completion. May 2021	Medium

BCG vaccination	NCT04414267	Greece	A Randomized double blinded Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial N=900 randomised to BCG or placebo	Positive for the respiratory questionnaire consisted of questions concerning the appearance of symptoms possibly, probably and/or definitively related to COVID-19 on visit 3. [Time Frame: Visit 3 (90 +/- 5 days)]	Recruiting; Estimated primary completion: May 25, 2021	Medium

Vaccine, Sponsor	**Study identifier/link to website**	**Location**	**Study design**	**Primary outcome**	**Status of trial**	**Importance**
Measles-Mumps-Rubella Vaccine Sponsor: Kasr El Aini Hospital	NCT04357028	Egypt	Phase 3, randomized, single-blinded, placebo-controlled clinical trial to determine the benefit of measles vaccine in health care professional. N = 200	COVID-19 disease incidence [Time Frame: Time Frame: Measured over the 6 months following randomization]	Not yet recruiting Estimated Study Completion Date: November 1, 2020	Medium
Inactivated mycobacterium vaccine Sponsor: Guangxi medical university	ChiCTR2000030016 http://www.chictr.org.cn/showproj.aspx?proj=49799	Guangxi Zhuang, China	N=60 with Covid-19 patients randomized to mycobacterium vaccine or saline	viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;	Recruiting Dec 12, 2022	Medium

Link to WHO's list of vaccines in preclinical and clinical phases, updated July 21, 2020:

https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines